Nanoparticulate delivery of LHRH analogue for the treatment of prostate cancer

References

• Fur BJA and Hutchinson FG. A biodegradable delivery system for peptides: preclinical experience with the gonadotrophin-releasing hormone agonist Zoladex. J of Cont Rel 1992; 21:117–128.
   Web of Science ®Google Scholar
• Briken P, Hill A, Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J Clin Psychiatry 2003;64:890–897.
   PubMed Web of Science ®Google Scholar
• Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer. Prostate 2000;45:158–166.
   PubMed Web of Science ®Google Scholar
• Schally AV, Halmos G, Rekasi Z, Arencibia JM. The actions of LH-RH agonists, antagonists, and cytotoxic analogue on the LH-RH receptors on the pituitary and tumors. In: Devroey P editor Infertility and Reproductive Medicine Clinics of North America. GnRH Analog. 2001; 12: 17– 44.
   Google Scholar
• Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5:447–457.
   PubMed Web of Science ®Google Scholar
• Persad R. Leuprorelin acetate in prostate cancer: a European update. Int J Clin Pract 2002;56:389–396.
   PubMed Web of Science ®Google Scholar
• Marks LS. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology 2003;62:36–42.
   PubMed Web of Science ®Google Scholar
• Croom KF, Perry CM. Leuprolide acetate once yearly subcutaneous implant in advanced prostate cancer. Am. J. Can. 2003;2: 57–64.
   Google Scholar
• Okada H, Doken Y, Ogawa Y, Toguchi H. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm Res 1994;11:1143–1147.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh J. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm 2007;328:42–48.
   PubMed Web of Science ®Google Scholar
• Zheng D, Li X, Xu H, Lu X, Hu Y, Fan W. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim Biophys Sin (Shanghai) 2009;41:578–587.
   PubMed Web of Science ®Google Scholar
• Li R, Li X, Xie L, Ding D, Hu Y, Qian X et al. Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int J Pharm 2009;379:158–166.
   PubMed Web of Science ®Google Scholar
• Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983;70:124–131.
   PubMedGoogle Scholar
• Herold DA, Keil K, Bruns DE. Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem Pharmacol 1989;38:73–76.
   PubMed Web of Science ®Google Scholar
• Hu Y, Jiang X, Ding Y, Zhang L, Yang C, Zhang J et al. Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)-poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. Biomaterials 2003;24:2395–2404.
   PubMed Web of Science ®Google Scholar
• Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000;18:301–313.
   PubMed Web of Science ®Google Scholar
• Tomar P, Karwasara VS, Dixit VK. Development characterizations and evaluation of Poly(-e-caprolactone)-based microspheres for hepatitis B surface antigen delivery. Pharm Dev Technol 2011;16:489–496.
   PubMed Web of Science ®Google Scholar
• Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 2007;67:1–8.
   PubMed Web of Science ®Google Scholar
• Li X, Li R, Qian X, Ding Y, Tu Y, Guo R et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm 2008;70:726–734.
   PubMed Web of Science ®Google Scholar
• Katare YK, Panda AK. Influences of excipients on in vitro release and in vivo performance of tetanus toxoid loaded polymer particles. Eur J Pharm Sci 2006;28:179–188.
   PubMed Web of Science ®Google Scholar
• Wei X, Gong C, Gou M, Fu S, Guo Q, Shi S et al. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm 2009;381:1–18.
   PubMed Web of Science ®Google Scholar
• Arulsudar N, Subramanian N, Mishra P, Chuttani K, Sharma RK, Murthy RSR. Preparation, characterization, and biodistribution study of technetium-99m labeled leuprolide acetate-loaded liposomes in ehrlich ascites tumor-bearing mice. A.A.P.S. Pharm Sci 2004; 6: 2–12.
   Google Scholar
• Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54:4091–4095.
   PubMed Web of Science ®Google Scholar
• Pályi I, Vincze B, Lovas S, Mezö I, Pató J, Kálnay A et al. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Proc Natl Acad Sci USA 1999;96:2361–2366.
   PubMed Web of Science ®Google Scholar
• Huang MH, Li S, Hutmacher DW, Schantz JT, Vacanti CA, Braud C et al. Degradation and cell culture studies on block copolymers prepared by ring opening polymerization of epsilon-caprolactone in the presence of poly(ethylene glycol). J Biomed Mater Res A 2004;69:417–427.
   PubMed Web of Science ®Google Scholar
• Kéri G, Balogh A, Szöke B, Teplán I, Csuka O. Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line. Tumour Biol 1991;12:61–67.
   PubMed Web of Science ®Google Scholar
• Debruyne FM, Dijkman GA, Lee DC, Witjes WP, del Moral F, Karthaus HF et al. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. J Urol 1996;155:1352–1354.
   PubMed Web of Science ®Google Scholar